AARTIPHARM vs LUPIN: Stock Comparison

Aarti Pharmalabs Limited vs Lupin Limited

Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Aarti Pharmalabs Limited shows a higher dividend yield, while Lupin Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Pharmalabs Limited and Lupin Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIPHARM is more favourable on 2 of 13 scored metrics and LUPIN on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.1 L Cr vs ₹6,133 Cr
P/E Ratio
LUPIN has a lower P/E
21.56x vs 36.57x
P/B Ratio
AARTIPHARM has a lower P/B
3.01x vs 5.12x
EPS
LUPIN has higher earnings per share
₹116.56 vs ₹19.26
Dividend Yield
AARTIPHARM has a higher dividend yield
0.57% vs 0.48%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 3.3%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs -30.8%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 3.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIPHARMLUPIN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIPHARMLUPIN
Live Price₹674.15₹2,407.5
Day Change-4.02%-4.27%
Volume1.81 L10.61 L
52-Week High₹969.5₹2,529.5
52-Week Low₹585₹1,836.8
Distance from 52W High-30.46%-4.82%

Valuation

MetricAARTIPHARMLUPIN
Market Cap₹6,133 Cr₹1.1 L Cr
P/E Ratio36.57x21.56x
P/B Ratio3.01x5.12x
EPS₹19.26₹116.56
Book Value₹234.28₹491.29
Dividend Yield0.57%0.48%

Growth

MetricAARTIPHARMLUPIN
Revenue Growth (TTM YoY)3.3%31.9%
EPS Growth (TTM YoY)-30.8%89%
Qtr Sales Growth3.35%31.9%
Qtr Profit Growth-30.8%101%

Profitability & Leverage

MetricAARTIPHARMLUPIN
ROE8.59%29.1%
ROCE10.7%30.3%
Net Margin10.25%17.65%
Operating Margin20.3%31.5%
Debt to Equity0.36x0.29x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIPHARMLUPIN
Promoter Holding42.69% 0.22 pp46.57% 0.04 pp
FII Holding8.17% 0.22 pp21.71% 0.22 pp
DII Holding7.22% 0.19 pp25.32% 0.26 pp
Public Holding41.74% 0.63 pp6.11% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Pharmalabs Limited and Lupin Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.